Skip to content

NCBIO Blog

Stay up to date with the latest from NCBIO

Recent Posts

Part D drug price “negotiation” comes at cost of jobs, investment, cures 

August 11, 2022

Congress passed the Inflation Reduction Act on Aug. 12. Included in the law is a provision that gives Medicare Part D the ability to “negotiate” the price of medicines for the first time. Negotiate is in quotation marks because lawmakers are being ironic; no one can legitimately call the new price-setting policy a negotiation.

Read More

BIO: CMS decision enormous setback for Alzheimer’s patients, dangerous infringement on FDA autonomy

April 8, 2022

On April 7, the Centers for Medicare and Medicaid Services held to its original decision to limit coverage of the Biogen’s Alzheimer’s disease treatment Aduhelm – along with other drugs like it – to clinical trials. Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement: “The National Coverage…

Read More

Biotech joins efforts to aid in humanitarian relief in Ukraine

March 4, 2022

The biotech and life sciences industry is coming together to donate a range of critical medical supplies, equipment, and medications to the people of Ukraine. “The conflict in Ukraine and violence from Russia defies international law, norms and modern sensibilities,“ said BIO President and CEO Dr. Michelle McMurry-Heath. “Unfortunately, those suffering the most are individuals…

Read More

CMS decision not to cover Alzheimer’s treatment a bad one

March 2, 2022

NCBIO stands in solidarity with patient advocates and industry leaders in opposing the Centers for Medicare and Medicaid Services’ draft proposal to restrict coverage for current and future Alzheimer’s drugs targeting beta amyloid, a known hallmark of the disease.  Restricting coverage is a bad idea for so many reasons:  CMS is competing directly with the…

Read More

Who pays to create new medicines?

January 13, 2022

Does government spending on drug development justify government price controls on medicines? Not when the private sector spends $102 billion on clinical R&D and the NIH spends less than $3 billion.

Read More

Laura Gunter: Biotech policies should protect patients, innovation

December 1, 2021

The ongoing response to the COVID-19 pandemic has highlighted the critical role of the North Carolina life sciences industry in battling our most serious public health threats. When faced with the threat of COVID-19, biotechnology companies – many based right here in North Carolina – answered the call and quickly developed safe and effective vaccines,…

Read More

Pharmaceutical Prescribing Labels: An Enormous Opportunity to Eliminate Pointless Paper Waste in the United States

November 22, 2021

A serious approach to addressing climate change must include the proactive elimination of unnecessary paper consumption. Paper is an important and useful material that should be produced and consumed in a responsible and sustainable way, and the existence of digital options that can be utilized safely and effectively should lead to the elimination of outdated…

Read More

BIO: Build Back Better Act weakens U.S. innovation ecosystem, hurts patients

November 19, 2021

Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and weaken the innovation ecosystem that has made America the leader in…

Read More

BIO: What happened with the Orphan Drug Tax Credit

September 17, 2021

During a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s BIO’s readout, including news on drug price controls and the…

Read More

BIO’s fall Congressional preview

September 8, 2021

The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.

Read More